文献速递消化道肿瘤放疗胸部肿瘤放疗

多西他赛联合顺铂对比5-氟尿嘧啶联合顺铂根治性同步放化疗治疗食管鳞状细胞癌患者:II期随机对照试验长期随访结果

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
PubMed 文献 · Radiat Oncol · 2023-09-12

这项II期前瞻性随机对照试验纳入86例临床II-IVA期食管鳞状细胞癌患者,比较DP方案与PF方案同步放化疗的疗效与毒性。5年随访显示,PF组与DP组5年总生存率分别为62.9%±7.6%和52.7%±7.5%(P=0.131),5年无进展生存率分别为43.9%±7.8%和40.0%±7.3%(P=0.398)。作者结论认为DP方案未改善治疗反应、总生存或无进展生存,PF方案仍为局部晚期食管鳞状细胞癌根治性同步放化疗的标准方案。

要点

  • PF组与DP组5年总生存率分别为62.9%±7.6%和52.7%±7.5%,差异无统计学意义(P=0.131)。
  • PF组与DP组5年无进展生存率分别为43.9%±7.8%和40.0%±7.3%,差异无统计学意义(P=0.398)。
  • 作者认为PF方案仍为局部晚期食管鳞状细胞癌根治性同步放化疗的标准方案。

核心结论

  • 5年随访证实,与PF方案相比,DP方案根治性同步放化疗未改善食管鳞状细胞癌患者的治疗反应、总生存或无进展生存。
  • 作者认为PF方案仍为局部晚期食管鳞状细胞癌根治性同步放化疗的标准方案。
  • 长期随访提示,适当且积极的挽救治疗可使部分患者获得生存获益,随访期间应注意晚期心肺毒性。

研究设计与样本

  • II期前瞻性随机对照试验,纳入86例临床II-IVA期食管鳞状细胞癌患者,来自中山大学肿瘤防治中心。
  • 患者分为PF组(41例)和DP组(45例),比较DP方案与PF方案同步放化疗的疗效与毒性。
  • 分析5年总生存和无进展生存,并总结挽救治疗与晚期毒性;试验注册号NCT02969473,注册日期2010年10月。

主要发现

  • PF组5年总生存率为62.9%±7.6%,DP组为52.7%±7.5%(P=0.131)。
  • PF组5年无进展生存率为43.9%±7.8%,DP组为40.0%±7.3%(P=0.398)。
  • DP组16例和PF组13例患者接受了挽救治疗;局部残留或局部复发疾病患者挽救治疗后的中位生存时间为13.5个月,1年、2年和3年生存率分别为79.0%、50.3%和43.1%。
  • 全部患者中13例(15.1%)发生2级晚期心脏毒性;1例患者发生2级胸腔积液并需要利尿剂;大多数肺炎患者症状轻微,仅PF组1例发生2级肺炎;DP组1例发生气管食管瘘。

临床怎么用

  • 作者结论认为PF方案仍为局部晚期食管鳞状细胞癌根治性同步放化疗的标准方案。
  • 作者认为适当且积极的挽救治疗可使部分局部残留或局部复发患者获得生存获益。
  • 作者指出随访期间应注意晚期心肺毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Definitive radiotherapy plus concurrent chemotherapy has been a standard treatment for esophagus patients who are unfit to undergo surgery. However, there are a variety of concurrent chemotherapy regimens with varying efficacy. In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS). We also summarized the salvage treatments and late toxicities. METHODS: We enrolled 86 patients with clinical stage II-IVA from the Sun Yat-sen University Cancer Center. The patients were divided into two groups: PF group (41) and DP group (45). Statistics were analyzed using SPSS version 19.0. RESULTS: The 5-year OS rates were 62.9% ± 7.6% in PF group, and 52.7% ± 7.5% in DP group (P = 0.131), respectively. The 5-year PFS rates were 43.9% ± 7.8% for PF group, and 40.0% ± 7.3% for DP group (P = 0.398), respectively. Sixteen patients in the DP group and thirteen in the PF group received salvage treatment. For those patients with local residual or local recurrent disease, the median survival time after salvage treatment was 13.5 months and the 1, 2, and 3-year survival rates were 79.0%, 50.3%, and 43.1%, respectively. For all patients, thirteen (15.1%) had Grade 2 late cardiac toxicities. One patient had Grade 2 pleural effusion and required diuretic. Most patients with pneumonia are mild, and only one patient in PF group had Grade 2 pneumonia. One patient in the DP group developed tracheoesophageal fistula. CONCLUSIONS: The 5-year follow-up confirmed that definitive CCRT with the DP regimen did not improve the treatment response, OS, or PFS in patients with ESCC compared to the PF regimen. The PF regimen remains the standard regimen for definitive CCRT for patients with locally advanced ESCC. Long-term follow-up also suggested that appropriate and active salvage treatment has a survival benefit for some patients, and late cardiopulmonary toxicities should be noticed during follow-up. TRIAL REGISTRATION: The trial was registered at https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT02969473, October 2010).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang H, Makelike K, Chen B, et al. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. Radiat Oncol. 2023. PMID: 37700348. doi:10.1186/s13014-023-02339-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。